Skip to main content

Latest

international business
Merck signs US$5.5-billion deal with Daiichi Sankyo for cancer therapy development
Daiichi Sankyo's company logo is pictured at its headquarters in Tokyo, Japan, October 20, 2023. REUTERS/Kim Kyung-Hoon
u.s. business
U.S. plans shift of Merck’s COVID-19 treatment to commercial market
FILE PHOTO: A COVID-19 treatment pill, called molnupiravir developed by Merck & Co and Ridgeback Biotherapeutics LP is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE HAS BEEN SUPPLIED BY A THIRD PARTY. MANDATORY CREDIT. THIS IMAGE WAS PROCESSED BY REUTERS TO ENHANCE QUALITY, AN UNPROCESSED VERSION HAS BEEN PROVIDED SEPARATELY./File Photo
advisor etfs
Expanding array of services for pets offers investors chance to get in on sector’s growth
Puppy dog pet
international business
Drugmaker Merck tops first-quarter expectations on Keytruda, Gardasil strength
FILE PHOTO: Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey, U.S., November 13, 2021. REUTERS/Andrew Kelly/File Photo
international business
U.S. FDA pauses initiation of new patients on Merck’s MS drug, sending shares plunging
FILE PHOTO: A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016. REUTERS/Ralph Orlowski
international business
Pfizer reportedly in talks to buy cancer drugmaker Seagen
FILE PHOTO: A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron
world
EU drug regulator recommends against approval for Merck’s COVID-19 pill for adults
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/
world
Merck and Moderna detail progress on potential skin cancer vaccine
FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. Shares of Merck and Moderna jumped early Tuesday, Dec. 13, 2022, after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study. (AP Photo/Seth Wenig, File)
world
Dozens of firms to make cheap version of Merck COVID-19 pill for poorer nations
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo
world
Merck’s at-home antiviral COVID-19 pill authorized by U.S. FDA
FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE HAS BEEN SUPPLIED BY A THIRD PARTY. MANDATORY CREDIT. THIS IMAGE WAS PROCESSED BY REUTERS TO ENHANCE QUALITY, AN UNPROCESSED VERSION HAS BEEN PROVIDED SEPARATELY./File Photo
market news
The close: North American markets rise as Omicron fears subside; ‘Santa Claus rally’ may be muted
A trader works on the floor of the New York Stock Exchange (NYSE) at the start of trading on Monday.
canada
Canada to manufacture Merck COVID-19 antivirals if regulator approves
Merck corporate headquarters in Kenilworth, N.J. Merck & Co. is shown on May 1, 2018. Merck Canada announced it plans to manufacture it's oral antiviral COVID-19 drug in Canada, making the country a global hub for the production of the potentially game-changing treatment. THE CANADIAN PRESS/AP-Seth Wenig
canada
Canada buying up to 1.5 million courses of oral anti-viral drugs to fight COVID-19
Public Services and Procurement Minister Filomena Tassi rises during Question Period, in Ottawa, Friday, Dec. 3, 2021. Tassi says Canada has signed agreements to buy up 1.5 million courses of oral antiviral treatment for COVID-19. THE CANADIAN PRESS/Adrian Wyld
international business
Pfizer, U.S. ink US$5.29-billion deal over possible COVID-19 treatment
FILE PHOTO: Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS NO RESALES. NO ARCHIVES. THIS IMAGE HAS BEEN SUPPLIED BY A THIRD PARTY./File Photo
world
Merck ahead of Pfizer in EU talks on COVID-19 pills
FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE HAS BEEN SUPPLIED BY A THIRD PARTY/File Photo
world
Pfizer says its experimental antiviral pill for COVID-19 cuts risk of hospitalization, death by 89%
(FILES) In this file photo taken on April 26, 2016, the Pfizer company logo at Pfizers headquarters in New York. - People who received Johnson & Johnson's Covid-19 vaccine may benefit from a booster dose of Pfizer or Moderna, preliminary results of a US study published October 13, 2021 showed. (Photo by Don EMMERT / AFP) (Photo by DON EMMERT/AFP via Getty Images)
world
Britain approves Merck’s COVID-19 pill in world first
FILE PHOTO: FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE HAS BEEN SUPPLIED BY A THIRD PARTY. MANDATORY CREDIT. THIS IMAGE WAS PROCESSED BY REUTERS TO ENHANCE QUALITY, AN UNPROCESSED VERSION HAS BEEN PROVIDED SEPARATELY/File Photo
international business
Antiviral pill effective in reducing COVID-19 hospitalizations, deaths, drugmaker says
FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. Merck is buying Acceleron Pharma in a deal worth about $11.5 billion. Merck said Thursday, Sept. 30, 2021, that it will pay $180 per share in cash for each Acceleron share. (AP Photo/Seth Wenig, File)
international business
Merck to buy Acceleron for about $11.5-billion in rare disease drugs push
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo
investment ideas
Warren Buffett’s Berkshire pares drug holdings, sheds Axalta, Biogen
Warren Buffett, CEO of Berkshire Hathaway Inc, pauses while playing bridge as part of the company annual meeting weekend in Omaha, Nebraska U.S. May 6, 2018.
u.s. business
Merck misses profit estimates, forecasts larger COVID-19 sales hit in 2021
FILE - In this Dec. 18, 2014, file photo, a person walks through a Merck company building in Kenilworth, N.J. COVID-19 infections weighed Merck with so many people avoiding visits to hospitals or even the doctor early in the first quarter. The pharmaceutical company on Thursday, April 29, 2021, reported first-quarter earnings of $3.18 billion.(AP Photo/Mel Evans, File)
u.s. business
Gilead, Merck collaborate to develop long-acting HIV treatment
FILE PHOTO: The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
u.s. business
Merck CEO Kenneth Frazier stepping down at the end of June
WASHINGTON, DC - FEBRUARY 26: Kenneth C. Frazier, chairman and CEO of Merck & Co. Inc., testifies before the Senate Finance Committee on "Drug Pricing in America: A Prescription for Change, Part II" February 26, 2019 in Washington, DC. The committee heard testimony from a panel of pharmaceutical company CEOs on the reasons for rising costs of prescription drugs. (Photo by Win McNamee/Getty Images)
u.s. business
Merck anti-baldness drug Propecia has long trail of suicide reports, records show
FILE PHOTO: A bottle of Propecia is seen on a pharmacy shelf in New York City, U.S., August 8, 2019. REUTERS/Zachary Goelman/File Photo
international business
Merck ends development of two potential COVID-19 vaccines
FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. The drugmaker will stop developing two potential COVID-19 vaccines after seeing poor results in early-stage studies. The company said Monday, Jan. 25, 2021, that it will focus instead on studying two possible treatments for the virus that also have yet to be approved by regulators. (AP Photo/Seth Wenig, File)
u.s. business
Merck signs $356-million U.S. supply deal for experimental COVID-19 treatment
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid
advisor stocks
How investors can take a bite out of animal health care
Happy Latin American family wearing facemasks while taking their dog to the vet during the COVID-19 pandemic
u.s. business
Merck sells stake in vaccine developer Moderna
Moderna's logo is reflected in a drop on a syringe needle in this illustration taken Nov. 9, 2020.
investment ideas
U.S. drugmaker earnings heat up this week with spotlight on vaccine news
An ampule of Ebola drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8.
european business
EU secures potential COVID-19 drugs from Roche, Germany’s Merck: source
The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/Files
international business
Merck to buy Austrian vaccine maker as it jumps into COVID-19 race
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo
number cruncher
Ten U.S. health care stocks leading the pack in 2020
For Number Cruncher column in Globe Investor/ROB only.
inside the market
Market movers: Stocks that saw action on Wednesday - and why
Marijuana plants are displayed for sale at Canna Pi medical marijuana dispensary in Seattle, Washington, November 27, 2012. Anthony Bolante/File Photo